Novartis' Zolgensma Had Manipulated Data In Application, US FDA Says
Executive Summary
Gene therapy should remain on the market, FDA says, but Novartis could face civil or criminal penalties. Firm knew of problems before approval.
You may also be interested in...
FDA Officials Cite Reasons For Denying Application Reviews Over Data Integrity Breaches
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
Novartis Shows Importance Of Gene Therapy With AveXis Name Change
Novartis has completed its absorption of AveXis and rebranded the acquired gene therapy specialist that developed the soon-to-be SMA blockbuster Zolgensma despite struggling to meet the data integrity standards of regulators and big pharma.
US FDA Decides Against Zolgensma Data Integrity Penalties As Novartis Bureaucratizes AveXis
Company’s promise to be more forthright, along with quality culture and policy upgrades, may have helped sway agency.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: